Molecular basis of macrolide-lincosamide-streptogramin (MLS) resistance in Finegoldia magna clinical isolates
- PMID: 32531434
- DOI: 10.1016/j.anaerobe.2020.102220
Molecular basis of macrolide-lincosamide-streptogramin (MLS) resistance in Finegoldia magna clinical isolates
Abstract
Of 69 clinical isolates of Finegoldia magna tested, 36% presented high-level MICs of erythromycin (>256 μg/ml), harboring erm(A) (n = 20) or erm(B) (n=5). Of nine isolates exhibiting an inducible resistance phenotype to macrolides-lincosamides-streptogramins B, four (44%) were susceptible with a potential risk of treatment failure due to emergence of resistant mutants.
Keywords: F. magna; GPAC; MLS; anaerobes; clindamycin; erm(A); erm(B).
Copyright © 2020 Elsevier Ltd. All rights reserved.
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources